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ABSTRACT 
 
Effects of the Anticoccidial Drug Amprolium on Broiler Breeder Performance and 
Enteric Health Following Coccidiosis Vaccination. (December 2010) 
Samantha Kaye Pohl, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. David J. Caldwell 
 
 Two experiments were performed to evaluate effects of amprolium 
administration at specific times and concentrations in replacement broiler breeders of 
three genetic lines vaccinated against coccidiosis.  Effects on performance parameters 
including body weight and flock uniformity, and post-vaccination oocyst cycling 
patterns were evaluated in addition to development of immunity following clinical 
Eimeria challenge according to gross and microscopic lesion scoring, post-challenge 
body weight gain (BWG), and total oocyst output.  Experiment one was conducted on 
fresh pine shavings while experiment two was conducted on used litter remaining in 
treatment pens from the first trial. 
 No significant differences were seen among treatment groups with regard to body 
weight in either trial.  Increased magnitude of oocyst shedding was observed in trial one, 
Line A with the group receiving amprolium on day 10.  Trends in the data indicated 
increased uniformity in Line A related to amprolium administration following day 21.  
The group in Line A receiving amprolium at day 10 showed a significantly lower degree 
of total oocyst output following challenge than the other medicated groups.  The group 
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receiving amprolium on day 10 in Line B showed significant reduction in post-
vaccination oocyst shedding following treatment in both trials while all shedding was 
delayed in trial two when compared to the first trial.  Effects on uniformity in Line B 
pullets varied between trials with trends indicating it being advantageous when used 
litter was a factor.  Higher post-challenge BWG was observed in Line B pullets 
administered the low concentration at day 16 than the controls.  Reductions in gross 
lesion development were seen in Line B pullets in both trials.  Line C pullets receiving 
the highest concentration of amprolium at day 16 showed significantly less uniformity in 
trial one while the controls appeared to perform better than all medicated groups in trial 
two.  All medicated groups in Line C exhibited delayed and increased magnitudes of 
oocyst shedding in trial two.  These data indicate that the effects of amprolium on 
performance and immunity development are variable according to genetic strain and 
indicated that administration may be influenced by litter condition. 
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CHAPTER I 
INTRODUCTION  
Avian coccidiosis is an enteric disease affecting the commercial poultry industry.  
This disease is caused by obligate intracellular protozoan parasites of the genus, 
Eimeria.  To date, nine species of Eimeria have been found to infect chickens including 
Eimeria maxima, E. acervulina, E. mitis, E. praecox, E. mivati, E. tenella, E. brunetti, E. 
hagani, and E. necatrix (McDougald and Fitz-Coy, 2008).  These parasites are 
responsible for invading the epithelial lining of the intestinal mucosa, resulting in 
pathological changes ranging from local destruction of the mucosa and underlying 
tissues to systemic effects such as blood loss, shock syndrome, and in some cases death 
(Vermeulen et al., 2001).  Coccidiosis infection within the industry results in dramatic 
economic losses each year, costing in excess of 800 million dollars (Allen and Fetterer, 
2002).  Costs are largely attributed to vaccination, prophylactic medication, and 
production losses associated with morbidity and mortality (Dalloul and Lillehoj, 2005; 
Williams, 1998).  Issues with avian coccidiosis have existed for more than sixty years, 
and despite constant advances in therapy and prevention these issues continue to plague 
the industry for a number of reasons.  The primary reasons being the nature of the 
parasite including its life cycle and mode of transmission in combination with host 
behavior and rearing environment.  The coccidian life cycle consist of three primary 
phases including sporogony, merogony, and gametogony (Lillehoj and Lillehoj, 2000).   
The infective oocyst resides in the intestine of the bird and is shed in the feces wherein it 
 
____________ 
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undergoes sporogony to develop into the infective stage of a sporozoite.  Each oocyst 
leads to the development of four individual sporozoites contained within the sporulated 
oocyst.  This sporulated oocyst is ingested by the bird from the litter, the individual 
sporozoites are released following ingestion and subsequently develop into oocysts 
within the digestive tract that are shed in the feces once more.  The specifics of the life 
cycle of each species of Eimeria can often be used as a valuable diagnostic tool when 
determining what species is responsible for the infection present (McDougald, 1998). 
 Multiple routes of control are currently available to the poultry industry including 
various types of anticoccidial drugs that can be administered via feed or water, as well as 
various types of vaccination.  A number of anticoccidial drugs have been employed at 
different times throughout the past 50 to 60 years, and include both ionophorous 
antibiotics produced by fermentation and synthetic compounds produced via chemical 
synthesis (Chapman, 1999).   
Vaccination has been used since the 1950s as an effective means of control for 
avian coccidiosis (Edgar, 1958; Shirley and Bellatti, 1988).  In the modern poultry 
industry, vaccination is most commonly utilized in broiler breeders and laying flocks.  
Its use in commercial broiler operations has thus far been limited due to the negative 
effects on growth and feed conversion initially seen in vaccinated birds.  The mode of 
action behind coccidiosis vaccination is the induction of an immune response that is 
responsible for enabling the birds to resist future challenges with virulent strains of 
Eimeria spp. without causing detrimental levels of infection (Chapman et al., 2005).  A 
single initial infection induced in an immunocompetent bird can be responsible for a 
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certain degree of immunity to reinfection, and is the reasoning behind coccidiosis 
vaccination (Rose & Long, 1962).  For complete protective immunity to be conferred, 
birds must be reexposed to the same strain of Eimeria initially used in vaccination.  This 
is achieved in the litter environment as the birds are exposed to the sporulated oocysts 
released in the feces following the initial cycle and shedding (Chapman et al., 2005). 
One chemical anticoccidial that has been used for control and prevention of 
coccidiosis is the chemical amprolium which acts as a thiamine analog that 
competitively inhibits the active transport of thiamine, negatively affecting Eimeria 
species without harming the bird due to the comparatively greater sensitivity of the 
parasite than the host to this exclusion.  Use of this chemical in pullet replacement flocks 
via water application has shown to be effective in alleviating the symptoms caused by 
coccidiosis infection without negatively affecting immunity development (Ruff and 
Chute, 1991).  The primary objective of this research was to determine what type of 
effect the administration of amprolium following industry standard methods of 
coccidiosis vaccination would have on the development of immunity and flock 
performance, body weight gain and uniformity, within a replacement pullet flock. 
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CHAPTER II 
REVIEW OF LITERATURE 
In today’s poultry industry, Eimeria species are the cause of extreme economic 
losses that have plagued the industry for many years.  Various aspects of the organism 
including its life cycle, host environment, and the resilient nature of the parasite have led 
to recurring issues associated with losses in body weight gain (BWG), decreases in flock 
uniformity, and decreases in feed efficiency in addition to other performance parameters 
associated with egg producing breeds such as laying stock and replacement breeders.  
Research is and has been constantly taking place in effort to discover new and improved 
ways to control and alleviate the symptoms resulting from infection by this parasite.   
The issues associated with coccidiosis in replacement broiler breeders have led to 
a variety of treatment and prevention methods including both vaccination and 
anticoccidial programs.  In some cases, the two of these are combined in order for the 
anticoccidial therapy to alleviate the performance losses associated with coccidiosis 
vaccination.  The following review discusses the specifics of the organism including life 
cycle, specificity, and pathogenicity, along with coccidiosis vaccination and 
anticoccidial treatments. 
History 
Coccidia possess a somewhat complicated history in the story of how they came 
to be a part of the taxonomic classification of which they are currently recognized.  The 
first coccidia were observed by Leeuwenhoek in the late 17th century and consisted of 
oocysts that were found in rabbit bile (Levine, 1982).  As a whole, the genus known as 
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Eimeria is the largest of the Eimeriidae family and belongs to the phylum Apicomplexa 
of the subkingdom Protozoa which is characterized by the presence of an apical complex 
in the sporozoite stage of the parasite.  All apicomplexans are characterized as 
intracellular parasites (Levine, 1982; McDougald and Fitz-Coy, 2008).  Members of the 
genus, Eimeria, are classified as having oocysts with four sporocysts, each with two 
sporozoites, and are considered homoxenous, meaning that all endogenous stages occur 
within a single host.  Of this genus there are approximately 1200 named species, capable 
of infecting and causing disease in a wide range of host organisms (Current et al., 1990).  
Coccidia of this genus are primarily host-specific with certain species infecting only a 
single host species or a group of closely associated hosts (Conway and McKenzie, 
2007).  Originally, the disease in chickens was believed to be caused by a single species, 
Eimeria avium (Edgar, 1958).  However, research performed by Tyzzer (1929) 
elucidated the fact that multiple species of Eimeria were capable of causing the disease 
in chickens as well as in other species.  There are currently nine species of Eimeria 
known to parasitize chickens: Eimeria acervulina, E. brunetti, E. maxima, E. mitis, E. 
mivati, E. necatrix, E. praecox, E. hagani, and E. tenella (McDougald and Fitz-Coy, 
2008).   
Life Cycle  
The nature of the coccidial disease contrasts with that of diseases caused by 
bacteria and viruses due to its self-limiting nature (McDougald and Fitz-Coy, 2008).  An 
example of this characteristic of coccidiosis was seen in surveys for coccidia present in 
broiler houses in Georgia when oocysts were shown to build up during the initial growth 
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of a flock and then to decrease as the birds gradually gained immunity to further 
infection (Reyna et al., 1983).  The omnipresent nature of poultry coccidia precludes the 
possibility of elimination from the environment or prevention of exposure by quarantine, 
disinfection, or sanitation (Calnek, 1997).    
The life cycle is comprised of asexual and sexual as well as parasitic and non-
parasitic phases and consists of both internal and external stages of development (Trees, 
2002; Hafez, 2008).  Life cycles of the various Eimeria species affecting chickens vary 
slightly in the number of asexual generations and the time required for each of the 
developmental stages, but are, in general, rather typical among all species (McDougald 
and Fitz-Coy, 2008).  The three main phases comprising the life cycle include that of the 
exogenous sporogony, and the endogenous merogony and gametogony (Hammond and 
Long, 1973).   
The internal stage is composed of all those parts occurring within the body of the 
host, beginning with the initial ingestion of the infective oocyst and ending with the 
excretion of the resulting oocysts in the fecal contents and includes the phases of 
schizogony (merogony) and gametogony.  Following the ingestion, the sporulated oocyst 
is crushed in the gizzard leading to the release of the formed sporocysts contained 
within.  Following their release, the actions of trypsin and bile in the duodenum serve to 
activate and release the sporozoites which then invade the epithelium of their designated 
region of the intestinal tract to develop and become trophozoites (McDougald, 1998).  
Prior to the clinical phase of infection, the parasite proceeds to the schizogony phase 
where multiple generations of daughter parasites known as schizonts are formed to move 
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onto the sexual phase of the life cycle.  The number of generations formed is dependent 
upon genetically predetermined characteristics of each individual species of Eimeria 
which can vary from two to four depending on the actual species (Current et al., 1990; 
Trees, 2002).  These gametocytes differentiate into biflagellated microgametocytes and 
macrogametocytes.  The microgametocytes divide asexually by multiple fission to form 
a large number of flagellated microgametes which migrate to the macrogametocytes in 
order to form macrogametes—this is the phase of gametogony (Levine, 1982).  These 
macrogametes then go on to be fertilized to form zygotes in the intestinal epithelium.  
Following the maturation of the formed zygote and the formation of the oocyst wall 
from the intracytoplasmic granules coalesced among the periphery of the oocyst; the 
mature oocyst is released into the intestine and excreted in the fecal contents of the bird 
(Trees, 2002; McDougald, 1998). 
The external stage is centered on the excreted oocyst and its development into an 
infective sporulated oocyst.  This part of the Eimeria life cycle is imperative, as 
reinfection cannot occur if the oocysts are not sporulated prior to ingestion (Hafez, 
2008).  After approximately 24 hours in the warm moist litter of the poultry house, 
oocysts sporulate and enter their infective state which consists of an oocyst containing 
four cysts known as sporocysts which each contain two infective parasites known as 
sporozoites (Fetterer and Barfield, 2003).  In order for an oocyst to undergo sporulation 
there are certain conditions that are required.  These conditions center on warmth, 
moisture, and oxygen.  For optimal sporulation conditions, the ideal temperature range is 
from 25 to 30°C, while freezing and heat in excess of 56°C are lethal (Trees, 2002).  
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While the ideal temperature range is relatively narrow, the additional conditions required 
for optimal growth are not as specific which leads to oocysts remaining viable in poultry 
litter for many months, and in some cases years (Hafez, 2008).  It is generally accepted 
that conditions of moist litter are favored for sporulation to take place (Card and 
Nesheim, 1972).  However, studies conducted to compare the optimal level of litter 
moisture have shown that this is not always the case.  Results have shown that oocysts of 
Eimeria acervulina vary only slightly in their rate of sporulation according to relative 
humidity (Graat et al., 1994).  Additionally, Waldenstedt and colleagues (2001) 
performed similar studies regarding the sporulation of oocysts of E. maxima which 
showed that their sporulation actually favored drier conditions. 
 In theory, according to the number of sporozoites in the mature, sporulated 
oocyst and taking into account the number of asexual and sexual reproduction stages that 
are involved in the life cycle of the Eimeria species, each oocyst is capable of producing 
2,520,000 second generation merozoites.  Each of these is able to develop into a macro-
or microgamont, but the actual number of oocysts produced per oocyst fed is 
considerably lower than that which is possible (Levine, 1982). 
Due to the nature of the life cycle of Eimeria species, the most common route of 
transmission is direct fecal-oral transfer, wherein the sporulated oocysts are ingested 
from the environment.  Sporulated oocysts may also be transmitted via mechanical 
routes by wild birds, insects or rodents that may be present in the environment, and by 
contaminated clothing, footwear, equipment, or dust (McDougald and Fitz-Coy, 2008). 
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Eimeria are both host specific, with the denoted species affecting only domestic 
chickens, and site specific, meaning that certain species parasitize specific regions of the 
gut and intestinal epithelia.  Certain exceptions have been noted, but only under 
experimental conditions such as those demonstrated by McLoughlin (1969) in his 
attempts to transmit E. tenella to turkeys and E. meleagrimitis to chickens.  The 
physiological reasoning behind the host specificity associated with this parasite is largely 
unknown, but generally understood to be a combination of genetic, 
nutritional/biochemical, and immune factors (Yun et al., 2000).  It should also be noted 
that while species of Eimeria are site specific and vary in the severity of their 
pathogenicity, interactions between different species as well as the condition of the host 
can have variable effects on the actual level of pathogenicity exhibited (Fernando, 1982).  
Investigations of this topic have led to the conclusions that while combined infections of 
varying concentrations of E. acervulina, E. brunetti, and E. maxima led to increased 
weight loss, competition between the species led to reduced oocyst production by 
individual species except in the instance that the species possessed entirely different 
infection sites (Hein, 1976).   
One of the most common species of Eimeria encountered in commercial poultry 
is E. acervulina which primarily attacks older chickens or replacement hens and 
possesses a low reproductive potential, meaning that the immunity which develops 
following infection is relatively weak (Pellérdy, 1974; Conway and McKenzie, 2007).  
This species manifests primarily in the mucosal epithelial cells of the duodenal loop, 
with gross lesions in light infections limited to that specific area.  During heavy 
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infections, however, it is possible for lesions to be found lower in the intestinal tract and 
to result in the destruction of the villous tips (McDougald and Fitz-Coy, 2008).  E. 
acervulina is reported to have two basic effects on the gut: an alteration of the intestinal 
structure and activity which leads to disturbances in absorption and intestinal 
permeability, as well as an indirect effect leading to reductions in feed and water 
consumption (Yvoré, 1972).  Mortality associated with E. acervulina infections is 
typically low, but due to the fact that infection disrupts normal digestive functions, 
affected birds show weight loss and reduced egg production (Pellérdy, 1974).  Another 
species which has a tendency to colonize the upper region of the small intestine is E. 
mivati.  This species was originally identified as, and continues to be, incorrectly 
diagnosed as a strain of E. acervulina, but was later named a separate species (Edgar and 
Seibold, 1964; Conway and McKenzie, 2007).  While E. mivati is considered to 
primarily infect the upper duodenal region of the intestine, this species is also commonly 
found throughout the intestinal tract extending even as far as the ceca and cloaca in the 
most severe infections.  E. mivati, like E. acervulina, affects the mucosal cells of the 
intestinal villi, but unlike E. acervulina, can be commonly found through the entire 
length of the villi (McDougald and Fitz-Coy, 2008).  Although infections of E. praecox 
are not typically known to result in notable gross lesion development, this species is 
recognized as one which affects the epithelial cells of the sides of the villi inhabiting the 
duodenal loop (McDougald and Fitz-Coy, 2008). 
There are two species of Eimeria that are noted for their infection in the mid-
small intestine.  E. maxima is considered one of the most commonly occurring species in 
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chickens while E. necatrix is referred to as one of the most virulent species afflicting 
chickens.  Both occur in the midgut, however E. maxima is most often found 
superficially in the epithelial cells of the intestinal mucosa with hemorrhages being 
found near the tips of the villi.  E. necatrix is a more invasive species with affected birds 
showing submucosa and lamina propria containing stages of coccidial development 
(McDougald and Fitz-Coy, 2008).  Another interesting characteristic of E. necatrix is its 
tendency to show different stages of development in different regions of the intestine, 
with the schizogonous generations occurring within the epithelium of the ileum and 
gametogony taking place in the surface epithelial cells of the ceca (Gregory, 1990). 
The species of Eimeria most notably affecting the lower region of the gut is that 
of E. tenella.  This is one of the most commonly known and often considered one of the 
most pathogenic species of coccidia due to its ability to cause large amounts of loss in 
commercial broilers as well as for its propensity of resulting in relatively spectacular 
gross lesion development.  E. tenella is generally associated with infections in younger 
chickens, and in very severe situations can lead to mortality as early as 5 to 6 days of age 
(Pellérdy, 1974).  It is only rarely that older birds develop infections from this species 
due to repeated exposure leading to a series of small infections which confer effective 
active immunity (Pellérdy, 1974).  This species is known to inhabit the villar epithelial 
cells and submucosa of the ceca of the chicken with the schizonts developing deep in the 
lamina propria, disrupting the mucosa and associated blood vessels, often destroying the 
muscularis mucosa (Joyner, 1982; McDougald and Fitz-Coy, 2008). 
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 Although there are inherent factors associated with each species of Eimeria that 
distinguish their respective levels of pathogenicity, a number of other factors must also 
be taken into account when evaluating the level of pathogenicity associated with 
individual species.  These consist of, but are not limited to, factors associated with the 
internal environment of the host as well as the outside environment acting on the parasite 
in addition to the factors associated with the genetic details and immunological status of 
the host (Joyner, 1982).  For example, the reaction of the host to infection is directly 
related to the number of sporulated oocysts which are ingested by the animal (Joyner, 
1982).  Increases in the number of oocysts ingested typically accompany an increase in 
the severity of infection (Long, 1973).  Several environmental factors such as litter 
moisture, outside temperature, and oxygen availability are capable of affecting the 
viability and infectivity of oocysts as well due to the fact that sporulation, which requires 
certain environmental conditions, is required for the oocyst to become infective. 
Diagnosis and differential identification of individual species of Eimeria 
parasitizing chickens can depend on several factors including the following: area of the 
intestinal tract being parasitized, the location of the parasite within the intestinal 
epithelium, gross appearance of the lesions resulting from infection, sporulation time, 
prepatent period, and morphology of the infective oocysts including size shape and color 
(Conway and McKenzie, 2007; McDougald and Fitz-Coy, 2008).  As stated previously, 
the appearance of the gross lesions resulting from coccidial infection vary according to 
species.  Lesions of E. tenella and E. necatrix are often considered to be the most notable 
of avian Eimeria species.  E. tenella lesions typically around five days post infection and 
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appear as hemorrhagic or whitish lesions in the ceca.  The contents of the ceca are 
known to coalesce, forming a semisolid core that can remain in the ceca for several days 
(Gregory, 1990).  This is often indication of a severe infection.  Lesions of E. necatrix 
occur throughout the intestine, mostly in the midgut, and often are observed as greatly 
hemorrhagic lesions with large amounts of blood and mucous accumulation in the 
intestine (Gregory, 1990).  E. maxima is known to create a certain amount of petechial 
hemorrhaging in the midgut that can often be observed from the serosal surface of the 
intestinal tract (Gregory, 1990).  Characteristic lesions of E. acervulina are discrete 
compared to certain other species, and are observed as whitish transverse lesions in the 
duodenal region of the intestine (Gregory, 1990). 
The oocysts included in the species of Eimeria known to affect chickens range in 
their size, shape, and morphology.  Sizes range from approximately 11×10µm up to 
21×17µm.  Of the commonly encountered species, E. mivati and E. acervulina are 
generally recognized as being the smallest in size; however E. acervulina oocysts tend to 
be more ovoid than spherical in shape as compared to E. mivati.  The largest oocysts 
belong to the species of E. maxima, E. tenella, and E. brunetti.  Of these three E. maxima 
and E. brunetti are more similarly ovoid in shape with the E. maxima oocysts possessing 
a slight yellowish shade when viewed microscopically, while E. tenella tends to have a 
more spherical appearance without color (McDougald and Fitz-Coy, 2008). 
Vaccination 
Options for Eimeria control in commercial poultry flocks are numerous, and 
consist of feed-based and drinking water-based anticoccidial drugs—ionophores as well 
14 
 
as synthetic chemicals—and live oocyst vaccination (Dalloul and Lillehoj, 2006).  
Problems of drug resistance, lack of new anticoccidial drugs, and consumer pressure to 
move away from drug use in animal feeds have forced the industry to focus more 
intently on the use of vaccination to combat coccidiosis (Hafez, 2008).  Live oocyst 
vaccination was developed in the 1950s and has since been used consistently in poultry 
production (Edgar, 1958).  Vaccines are currently used extensively in the rearing of 
broiler breeders and replacement layer stock (Chapman, 2000; Chapman et al., 2002).  
The purpose of vaccination is to induce an immune response that is capable of enabling 
birds to resist challenges with virulent, heterologous infections—whether they be natural 
or experimental (Chapman et al., 2005).  Options for immunization vary widely; 
however, there are a limited number that are recognized as commonly used methods of 
control within the commercial poultry industry (Trees, 2002).  The methods available 
include: 1) chemically modulated, natural infection wherein layer and breeder stock are 
raised on litter prior to sexual maturity to encourage coccidial exposure while 
modulating infection with anticoccidial drugs; 2) live, unattenuated vaccines 
administered in water that contain mixtures of unattenuated lines of oocysts of the 
species considered important; 3) live, attenuated vaccines that are available with all 
important precocious Eimeria species of chickens having been attenuated so that they 
have lost virulence, yet retain immunogenicity; 4) killed or non-living vaccines which 
have been an important topic of research and involve the use of vaccines containing 
important antigens of certain species of Eimeria to confer immunity to exposed birds 
(Trees, 2002).  No matter the type of immunization administered, the objectives to be 
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achieved by vaccination should: induce protective immunity, be safe for target species, 
not pose an environmental hazard, consist of parasites of normal or low virulence that 
remain viable through optimal storage conditions, protect against field strains from 
different geographical areas, be administered by practical methods, have no negative 
effects on performance, be compatible with other vaccines administered, be free from all 
types of contaminants, be cost effective, and include drug sensitive lines in order to 
reduce drug resistance (Chapman et al., 2005). 
Due to the fact that the immunity conferred by these vaccines is incredibly 
species specific, it is necessary to incorporate multiple species of Eimeria within the 
vaccine.  For birds reared for extended periods of time such as broiler breeders and 
laying replacements, it is necessary to include certain species that might not be necessary 
for birds such as broiler flocks that do not live for an extended period of time.  Such 
species include E. brunetti, and E. necatrix due to their lack of manifestation in younger 
flocks of birds, as well as E. praecox which is considered less pathogenic than other 
species (Chapman et al., 2005).  Broiler breeders are more likely to encounter certain 
species of Eimeria, and should therefore be immunized against all possible coccidial 
species (Shirley & Millard, 1986; Williams, 1998). 
Live, unattenuated vaccines have been suggested to induce long-lasting 
protective immunity by stimulating a range of immune responses found to take place 
when birds are naturally infected (Chapman et al., 2005); however, drawbacks of their 
use include the inherent pathogenicity and the fact that only limited amounts can be 
safely administered to young chicks.  To address this issue, live, attenuated vaccines 
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were developed.  Attenuated vaccines function under the same mechanisms as non-
attenuated vaccines except the oocysts included in the attenuated vaccines include those 
which have been characterized as precocious by exhibiting reduced prepatent periods, 
decreased reproductive potential, and diminished infectivity (McDougald et al., 1986).  
Attenuation is most commonly achieved by in vivo passage of parental strains, selection 
for early oocyst development, and parasite irradiation (Lillehoj and Lillehoj, 2000).  
Killed vaccines can contain a large number of immunogens responsible for and capable 
of inducing humoral immune responses, however they typically lack the critical 
components associated with intracellular developmental stages that are needed to 
activate cell mediated immunity (Yun et al., 2000).   
The premise behind live oocyst vaccine use is the stimulation of host immunity 
that develops from low level Eimeria infection (Yun et al., 2000).  For this immunity to 
effectively develop it is necessary that the parasite be introduced into the gastrointestinal 
system of the bird for merogony and gametogony to occur, the oocyst be shed onto the 
litter, sporulated, and re-ingested by the bird (Chapman and Cherry, 1997).   
Methods of application for live oocyst vaccines are numerous and include spray 
application either in the hatchery or at the farm prior to placement, inclusion in edible 
gel that is provided at the hatchery or farm, spraying onto the first feed given after 
placement, injection into amniotic fluid at late stages of embryonic development, 
injection into yolk sac of freshly hatched chicks, ocular administration or drinking water 
administration (Chapman et al., 2005).  However, the more common route of application 
in commercial hatcheries is that in which oocysts are introduced to the bird via spray 
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application in a commercial spray cabinet of a predetermined volume of liquid 
suspension containing the oocysts (Chapman et al., 2002).  Birds are then allowed to 
preen and ingest the oocysts.  Approximately one week following vaccination, viable 
oocysts are excreted onto the litter for sporulation and re-ingestion, a process necessary 
for solid immunity development (Chapman, 2000).  One of the most important criteria 
for choosing the best method of vaccination is to ensure that all birds receive the 
appropriate intended dose of the vaccine (Chapman et al., 2002). 
Although live oocyst vaccination has been a successful means for the control of 
coccidiosis, especially in breeders and laying stock, there are concerns associated with 
use in the industry.  One of the primary disadvantages associated with the use of 
coccidiosis vaccination is their association with depression of performance parameters 
including BWG and feed conversion early on in bird development (Mathis, 1999).  This 
period of performance loss is associated with the mild infection that is necessary in the 
bird in order to stimulate immunity development (Danforth et al., 1997).  Another 
drawback associated with use of non-attenuated vaccines is the development of clinical 
coccidiosis when the number of oocysts in the environment increases at a pace which 
exceeds that which is controllable by the development of acquired immunity (Chapman, 
2000).  One solution to these problems may be the concomitant administration of an 
anticoccidial drug which is capable of controlling the clinical infection without 
suppressing the development of immunity within the host (Chapman, 2000; Williams, 
2002).  It has been said that the combination of chemoprophylaxis with vaccination 
could be useful due to the fact that drug resistant strains which may be present in the 
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environment would be controlled by vaccination while the sensitive strains would be 
controlled by the drug (Danforth, 1998).  There are even reports of certain vaccine 
manufacturers that have been shown to recommend subsequent treatment with 
anticoccidial drugs following vaccination in order to suppress post-vaccinal reactions 
(Chapman and Cherry, 1997).  Another option for alleviating the decline in performance 
associated with coccidiosis vaccination is the use of attenuated vaccines with precocious 
strains of Eimeria organisms.  These vaccines are capable of inducing protective 
immunity while avoiding the decline in performance that is occasionally seen in more 
commonly used vaccination strategies (Crouch et al., 2003). 
While concomitant use of anticoccidial drugs and coccidiosis vaccination can be 
advantageous in certain instances, improper timing or excessive administration of 
anticoccidial compounds can have negative effects on the performance of coccidiosis 
vaccines.  As stated, immunity development is reliant upon the successful cycling of the 
Eimerian parasite within the host organism, and if the parasites are incapacitated prior to 
the completion of their life cycle in its entirety, that immunity development is inhibited.  
Therefore, it is imperative that any anticoccidials administered with the intentions of 
alleviating the negative effects of vaccine administration be carefully employed. 
Anticoccidials 
 It was originally discovered that certain drugs could be used in the treatment of 
coccidiosis in 1939 when Levine discovered the successful administration of 
sulfanilamide in chickens; however, treatment was not applied widely across the 
agricultural industry until after the Second World War (McDougald, 1982).  At this point 
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in time, changes in the chemical industry allowed decreases in chemical production 
which led to successful implementation of sulfaquinoxaline for the prevention of 
coccidiosis in chickens (Grumbles et al., 1948).  Since then, innumerable amounts of 
anticoccidials have been implemented at one point or another within the poultry 
industry.  While the mode of action, method of administration, and resulting effect on 
the disease may vary, all of the drugs have been developed and used with the common 
intent of alleviating the burdens to the industry that coccidiosis has presented.  Since 
their inception, these anticoccidial agents have led to a major growth in the poultry 
industry due to their ability to achieve this goal (Allen and Fetterer, 2002). 
 There are two separate types of anticoccidials used within the industry including 
synthetic drugs produced by chemical synthesis and ionophores, which are produced via 
fermentation.  While synthetic anticoccidials operate via a specific mode of action 
associated with parasite metabolism, ionophores act through alteration of membrane ion 
transport which leads to disruption of osmotic balance within the parasite (Chapman, 
1999; Allen and Fetterer, 2002).  Another difference between the two classes of 
anticoccidials is the stage of the Eimerian life cycle that they are typically effective in 
controlling.  Generally speaking, anticoccidials are known to act against the asexual 
stages of the parasite (Chapman, 1993).  Ionophores typically target sporozoites, but 
merozoites have shown to be affected in certain instances as well.  Effects against 
sporozoites are a result of the interruption of important physiological balances such as 
that of sodium and potassium ions (McDougald, 1990).  Additionally, chemical 
anticoccidials are typically thought to have action against the later stages of the Eimerian 
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life cycle.  Several examples exist in terms of approved drugs for both types of 
chemotherapy.  For instance, some synthetic anticoccidials may include amprolium, 
nitrobenzamides, as well as folate antagonists and inhibitors while examples of 
ionophores include monensin, narasin, and salinomycin.  Generally speaking, most drugs 
used in Eimeria control are effective against only certain species of the parasite, while 
not as effective against others. This has resulted in the use of a combination of drugs in 
many instances. 
 Although anticoccidials have historically proven to be effective in the battle 
against coccidiosis in the broiler industry, one issue that continues to contradict this 
effectiveness is that of drug resistance which is defined as the ability of a parasite strain 
to multiply or survive in the presence of concentrations of a drug that would typically 
destroy parasites of the same species or prevent their multiplication.  Resistance has 
been shown to develop wherever chemicals are used extensively to control the disease, 
and due to the fact that anticoccidials are constantly implemented in poultry production, 
this is an industry that has experienced its share of issues regarding drug resistance.  
Medication through feed and/or drinking water is considered cost effective and 
convenient in poultry production, and is therefore used in almost all production in the 
United States.  Two types of resistance have been identified over time and include an 
acquired resistance that consists of a gradual decline in the level of sensitivity to a 
certain drug, as well as an innate resistance.  The innate resistance constitutes a certain 
strain or species’ lack of sensitivity to certain drugs (Chapman, 1997).  McDougald 
(1982) has reported that subtle differences exist in regard to various ionophores against 
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different species of Eimeria.  In the present poultry industry nearly every drug that has 
been discovered and developed to combat avian coccidiosis has, at some point, produced 
a certain level of drug resistance (Chapman, 1997).   
 There are several programs that have been implemented within the young layer 
and replacement breeder areas including feeding suboptimal concentrations of certain 
anticoccidials on alternate days in restricted feeding programs which allowed for the 
shedding of enough oocysts to impart immunity in affected birds while preventing 
detrimental outbreaks, using drugs that have lost effectiveness, using ‘step-down’ 
programs in which the concentration of the drug being administered is gradually 
decreased, using a drug intermittently, or using drugs only in therapeutic instances when 
birds are showing signs of clinical coccidiosis infection (Reid et al., 1968; Long, 1979).  
Anticoccidial programs which allow for immunity development are vital in these classes 
of birds—especially when they are in a floor-rearing situation and thus have access to 
feces—due to the fact that any anticoccidial drugs that are being administered are 
subsequently removed at the point when the bird enters its laying period (Chapman, 
1999).   
Amprolium Treatment 
Since its introduction in 1960 that the chemical anticoccidial amprolium 
possessed a high level of effectiveness against various species of Eimeria, namely E. 
tenella, E. necatrix, and to a lesser extent, E. maxima (Cuckler et al., 1960, McDougald, 
1982).  Amprolium is effective in the prevention of production, sporulation, and 
infectivity of Eimeria oocysts (Ruff et al., 1993).  Additionally, amprolium 
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administration has been shown to protect affected birds from the negative effects on 
BWG associated with coccidial infection and to prevent mortality in affected birds while 
conferring complete protection against various levels of Eimeria infection (Singh and 
Gill, 1976; Prasad et al., 1986; Chapman, 1989).  Amprolium acts as a selective thiamine 
antagonist, competing with the parasite for the absorption of thiamine, and thereby 
controlling its proliferation in the host (Ryley and Betts, 1973; McDougald, 2003).   
It has been suggested that amprolium is a suitable option in the instance of 
rearing replacement breeder flocks due to the fact that it would allow immunity 
development when high build up of infection is available in floor pens (Chapman, 1999).  
In fact, amprolium is one of two drugs in the United States whose use is suggested for 
the development of active immunity, and for which various step-down programs using 
different concentrations of drug are approved for this purpose (Anon, 1997).  The 
concern resides in situations where lower levels of infection are present, leading to the 
impediment of immunity development (Singh and Gill, 1976).  Evidence of this issue 
was brought to light by Bajwa and Gill (1977), who administered amprolium at a rate of 
0.024% via drinking water, and found that a possible interference with the development 
of immunity to infections with small numbers of oocysts actually did exist.  Counter to 
those results, however, are those reported by Hu and colleagues (2000) who found that 
amprolium administration took place without interfering appreciably with protective 
immunity development in broilers.  Additionally, Ruff and colleagues reported that when 
amprolium was administered via water while feed intake was restricted, protection 
against coccidiosis was provided while immunity development was not hindered (Ruff 
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and Chute, 1980; Ruff and Chute, 1991).  With regard to this information, there remains 
a degree of disagreement in the timing of liquid amprolium administration for the use of 
controlling possible pathogenic effects of the non-attenuated vaccines.  Select sources 
state that amprolium should be administered beginning ten days after vaccine 
administration (Chapman, 1999; 2000; Chapman and Cherry, 1997) while others believe 
that administration of amprolium should begin 16 – 17 days after vaccination in order to 
reduce the reaction to infective oocysts without disrupting the cycling of the parasite and 
the development of immunity (Chapman et al., 2002).   
Therefore the objective of this research trial is to determine and compare the 
effects of amprolium administration at different times and concentrations in vaccinated 
replacement broiler breeders on BWG, flock uniformity, oocyst cycling, and immunity 
development.  Information obtained from these trials could benefit the industry by 
providing knowledge about the interactions of vaccination and chemical anticoccidial 
administration and how they impact the development of immunity to clinical Eimeria 
infections in commercial production. 
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CHAPTER III 
IMPACT OF AMPROLIUM ADMINISTRATION ON OOCYST CYCLING AND 
PERFORMANCE PARAMETERS IN COCCIDIOSIS VACCINATED 
REPLACEMENT BROILER BREEDERS 
Introduction 
 Coccidiosis is a major disease condition affecting the poultry industry, resulting 
in significant economic losses in excess of 800 million dollars each year (Allen and 
Fetterer, 2002).  The majority of these costs are associated with performance losses in 
the form of growth depression and decreased feed efficiency due to the organism’s 
invasion of the intestinal epithelium of the host which results in decreased nutrient 
absorption.  Due to the nature of the organism and its ubiquitous nature in the rearing 
environment, this is not a disease that will soon be eradicated (Yun et al., 2000).  The 
best option available to today’s poultry industry is to implement all available and 
feasible control measures for treatment and prevention.  
 Current options for coccidiosis control include vaccination and anticoccidial drug 
administration.  In replacement breeding stock vaccines are used extensively to control 
coccidiosis (Chapman, 2000; Chapman et al., 2002).  The idea behind live oocyst 
vaccination is to impart a low level of Eimeria infection in order to stimulate immunity 
(Yun et al., 2000).  Live, unattenuated vaccines have been suggested to induce long-
lasting protective immunity by stimulating a range of immune responses when birds are 
infected by vaccine strain Eimeria (Chapman et al., 2005).  For immunity to develop it is 
necessary to introduce the parasite into the host’s system, complete its life cycle, and be 
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excreted onto the litter for re-ingestion by the host (Chapman and Cherry, 1997).  The 
primary disadvantage associated with coccidiosis vaccination is the associated period of 
performance loss associated with the mild infection that is necessary for immunity 
development (Mathis, 1999; Danforth et al., 1997).  
The reason for concern associated with live oocyst vaccination in replacement 
flocks is due to this possibility of negative implications on body weight gain (BWG) and 
feed efficiency.  There are several factors to consider in the rearing and successful 
management of replacement broiler breeders, with the most important being control of 
average body weight, uniformity, and disease development.  This is due to the early 
rearing period being a critical time for the establishment of appropriate frame and body 
weight of the bird (Hudson et al., 2001).  If these details are not taken into careful 
consideration, negative effects can be observed by the level of reproductive efficiency 
following the onset of sexual maturity. 
 One option for alleviating some of the performance losses associated with live 
oocyst vaccination in breeders involves the concomitant administration of an 
anticoccidial drug capable of controlling the clinical infection without suppressing the 
development of host immunity (Chapman, 2000; Williams, 2002).  Certain vaccine 
manufacturers have gone as far as to recommend treatment with anticoccidials following 
vaccination in order to suppress post-vaccinal reactions (Chapman and Cherry, 1997).  
Amprolium administration has been shown to protect affected birds from the negative 
effects resulting from coccidial infection while allowing for complete immunity 
development against Eimeria infection (Singh and Gill, 1976; Prasad et al., 1986; 
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Chapman, 1989).  However, while previous research has been performed to address this 
topic, a great deal of time has passed since, and with that several changes in bird 
genetics, nutrition and feeding, breeder management practices, and changes in the 
parasite have come as well.  These facts have led to the need for further investigation of 
the topic.  Therefore, the objective of the current study was to determine and compare 
the effects of different concentrations of amprolium administered at different time points 
via drinking water on BWG, flock uniformity, and oocyst cycling in coccidiosis 
vaccinated replacement broiler breeders from placement to 35 days of age.   
Materials and Methods 
Experimental Design 
 This experiment was conducted in an environmentally controlled dark-out 
growing facility at the Texas A&M University Poultry Science Teaching, Research, and 
Extension Center in College Station, TX.  Animal care and husbandry were provided in 
accordance with an approved Texas A&M Institutional Animal Care and Use (IACUC) 
protocol.  Both trials of this experiment followed an experimental design consisting of 
four treatment groups present in each of three genetic lines of birds.  Five replicate pens 
were placed for each treatment group for a total of 60 pens.  The three genetic lines of 
the replacement broiler breeder females evaluated in these trials are denoted as Lines A, 
B, and C.  Of the four treatment groups (Table 3-1), one group was administered 
amprolium from days 10 through 12 at a concentration of 0.006%, another was 
administered from day 16 through 18 at the same concentration, while the other was 
administered from day 16 through 18 at a concentration of 0.012%.  A negative control 
27 
 
was maintained for each genetic line in which access to the municipal water source used 
on our research farm was maintained for the duration of the trial.  Experimental 
parameters evaluated included BWG, flock uniformity, and oocyst shedding associated 
with vaccination (oocysts shed per gram (OPG) of feces). 
Body Weight Gain and Flock Uniformity 
 Performance was assessed according to individual bird weights and compared to 
line specific target body weights (Table 3-1) at day of placement, as well as 7, 10, 14, 
16, 21, 28, and 35 days post placement.  Individual body weights were also used to 
determine variability by pen and to assess total flock uniformity. 
 
 [Table 3-1] Target body weights (g) for all genetic lines investigated, according to age, 
up to 35 days. 
 Age (d) 
 7 14 21 28 35 
Line A 109 213 309 400 490 
Line B 159 281 400 522 622 
Line C 136 272 363 454 545 
      
 
Oocyst Shedding (OPG Determination) 
 Beginning on day 5 of each trial, and continuing on an every-other-day basis 
through termination of each trial, feces were collected from four pens from each of the 
treatment groups.  These four samples were then pooled into two pen samples for 
examination and quantification of oocysts present per each gram of fecal contents.  Prior 
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to analysis, each pooled fecal sample was homogenized, weighed, and diluted at a 3:1 
ratio of water to fecal matter.  From each sample, 10 µL of fecal suspension were 
extracted and loaded into a hemacytometer using a 200µL pipette to be observed 
microscopically for oocyst presence.  A standard light microscope and a 20× objective 
were used to quantify non-sporulated oocysts present in each sample for oocyst per gram 
of feces (OPG) calculations. 
Experimental Animals and Rearing 
Broiler breeder pullets of each line evaluated were obtained at day of hatch from 
commercial hatcheries.  Following normal services and processing, chicks were 
transported to the research rearing facility, wing-banded for identification, weighed 
individually, and randomized according to weight.  Randomization was performed by 
removing the heaviest and lightest 5% of each strain of birds and then randomly 
distributing the remaining pullet chicks to allow for an evenly distributed starting pen 
weight for each pen.  Chicks were placed on fresh pine shavings for initiation of the first 
trial.  In the second trial, chicks were obtained and placed on used shavings remaining in 
rearing pens from the previous trial.  Chicks were placed at a density of 1.5 ft2/bird, in 
agreement with industry standards.  For the first 14 days of each trial, chicks were 
allowed access to only half of the final pen space to mimic half house brooding.  On day 
14 all barriers were removed and birds were allowed full pen access through 35 days of 
age.  Each pen was equipped with appropriate feeders and commercial-style nipple 
drinking systems.   
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In both trials chicks were provided appropriate supplemental heat, water, and 
breeder specific starter diets according to their respective feeding schedules (Table 3-2) 
in order to maintain breeder recommended target weights.  All strains were fed ad 
libitum through 14 days of age, fed daily allocations through 28 days of age, and 
subjected to a 3/4 skip-a-day feeding regime for the remainder of the trial.  Breed 
specific starter diets were fed through day 28, after which breed specific grower diets 
were fed.   
 
[Table 3-2] Feed allocation on a per bird, per day basis for each genetic line, by week, 
through 5 weeks of age. 
 
Line 
Age (wk) 
1-2 3 4 5 
 Trial 1 
Line A ad libitum 32g 35g 38g 
Line B ad libitum 36g 44g 48g 
Line C ad libitum 36g 42g 43g 
 Trial 2 
Line A ad libitum 32g 38g 40g 
Line B ad libitum 36g 42g 46g 
Line C ad libitum 39g 43g 44g 
     
 
 All pullets were housed in a dark-out grower facility and subjected to an industry 
specific schedule of time and light intensity as measured by a photometer.  For the first 
three days chicks were exposed to 24 hours of light at an intensity of 30 lux.  From day 4 
through 7 light was reduced to 18 hours per day at an intensity of 20 lux.  From day 8 
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through day 21 lights were again reduced to 12 hours per day at the same intensity.  
From day 22 through the remainder of each trial light was reduced to 8 hours per day at 
an intensity of 10 lux.  
Vaccination and Amprolium Administration 
 The commercially available coccidiosis vaccine Coccivac®-D (Intervet/Schering-
Plough Animal Health; Summit, NJ) was used in these trials.  This vaccine, a non-
attenuated live oocyst coccidiosis vaccine for replacement broiler breeders and laying 
stock, was administered at the manufacturer recommended dose of 0.25 mL/bird on day 
of hatch using commercial spray cabinet in the commercial hatchery providing each 
genetic line of replacement breeders. 
 In both trials, each genetic line of pullets received the synthetic anticoccidial 
compound amprolium (Amprol® 9.6% Oral Solution; Huvepharma; Sofia, Bulgaria) 
according to one of four administration protocols.  One group of each genetic line was 
maintained as a negative control while the three amprolium administrations consisted of 
a 0.006% concentration on days 10 through 12, a 0.006% concentration on days 16 
through 18, and a 0.012% concentration on days 16 through 18.   On the specified day 
birds were switched from main line water sources and given access to an unlimited water 
supply containing the specified concentration of medication.  The medicated water 
supply was refreshed and replenished every 24 hours for the duration of each 
administration period.   
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Statistical Analysis 
The experimental parameters from this trial were subject to a one way ANOVA 
(SPSS v. 11).  Means were separated using Duncan’s Multiple Range test and deemed 
statistically different at p ≤ 0.05 (SYSTAT, 2001). 
Results 
Trial 1 
With regard to flock uniformity, no significant differences were observed for 
lines A or B on any of the data collection days (Tables 3-3 and 3-4).  However, trends 
were observed on day 21 (p=0.11), day 28 (p=0.10), and day 35 (p=0.08) which 
indicated potential increases in uniformity relevant to the control and 0.006% amprolium 
on days 16 through 18.  A significant (p ≤ 0.05) improvement in Line C flock uniformity 
was observed on days 21, 28, and 35 in the control group and both 0.006% amprolium 
concentration groups when compared with the 0.012% concentration administered from 
day 16 through 18 (Table 3-5).  With regard to body weights at all data collection days, 
no significant differences were observed between treatment groups among any of the 
genetic lines. 
All peaks occurring in oocyst shedding for Line A pullets were observed 
following day 15.  The first set of peaks in oocyst shedding, which occurred between 
days 19 and 21 showed a decreased level of shedding in the 0.006% amprolium 
concentration on both days 10 to 12 and 16 to 18.  In addition to this decrease in oocyst 
shedding, further depression was observed in the 0.012% concentration treatment group 
(Figure 3-1).  For the second set of peaks, which occurred between days 24 and 26,  
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Table [3-3] Trial 1—Body weights and flock uniformity of Line A replacement pullets vaccinated with a live oocyst vaccine 
administered different concentrations of amprolium at different time periods through 35 days of age reared on fresh pine 
shavings. 
 
 Age (d) 
Treatment 0 10 16 21 28 35 
  
Body Weight (g) 
 
Control 
 
40.6 ± 0.0    175.3 ± 1.6 306.9 ± 1.9  341.8 ± 0.8 444.1 ± 6.1 583.4 ± 6.8 
0.006%@d10-12 
 
     301.4 ± 3.8 334.3 ± 3.3 434.2 ± 1.9 578.3 ± 9.8 
0.006%@d16-18 
 
         330.1 ± 10.8 441.2 ± 7.0 599.7 ± 10.4 
0.012%@d16-18 
 
         337.4 ± 6.4 440.1 ± 9.4 586.8 ± 31.0 
 Flock Uniformity  
(Coefficient of Variation) 
 
Control 
 
5.4 ± 0.1 17.3 ± 1.0    14.6 ± 0.6   14.5 ± 0.9 13.3 ± 1.2 13.9 ± 1.2 
0.006%@d10-12 
 
    14.9 ± 1.8 13.5 ± 1.9 12.7 ± 1.4 12.9 ± 1.1 
0.006%@d16-18 
 
       12.5 ± 0.6 13.0 ± 0.6 13.7 ± 0.9 
0.012%@d16-18 
 
      13.5 ± 1.4 11.8 ± 1.7 12.3 ± 1.5 
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Table [3-4] Trial 1—Body weights and flock uniformity of Line B replacement pullets vaccinated with a live oocyst vaccine 
administered different concentrations of amprolium at different time periods through 35 days of age reared on fresh pine 
shavings. 
 
 Age (d) 
Treatment 0 10 16 21 28 35 
  
Body Weight (g) 
 
Control 
 
 39.4 ± 0.1   204.6 ± 3.5  340.8 ± 2.7  370.9 ± 5.0 501.7 ± 3.7 713.4 ± 11.7 
0.006%@d10-12 
 
  334.4 ± 13.3 372.8 ± 8.7 503.2 ± 11.7 716.6 ± 45.3 
0.006%@d16-18 
 
     368.5 ± 10.0 498.7 ± 4.7 688.5 ± 9.1 
0.012%@d16-18 
 
     366.7 ± 9.3 506.4 ± 4.3 701.6 ± 5.4 
 Flock Uniformity  
(Coefficient of Variation) 
 
Control 
 
5.9 ± 0.1  12.1 ± 0.7  11.3 ± 0.5    9.2 ± 0.9 9.1 ± 0.8 9.1 ± 0.7 
0.006%@d10-12 
 
  12.5 ± 0.9 10.9 ± 0.9 10.8 ± 0.6 11.2 ± 0.7 
0.006%@d16-18 
 
       8.9 ± 0.2 9.2 ± 0.4 10.6 ± 0.8 
0.012%@d16-18 
 
     11.5 ± 1.0 10.7 ± 0.5 12.1 ± 0.8 
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Table [3-5] Trial 1—Body weights and flock uniformity of Line C replacement pullets vaccinated with a live oocyst vaccine 
administered different concentrations of amprolium at different time periods through 35 days of age reared on fresh pine 
shavings. 
 
 Age (d) 
Treatment 0 10 16 21 28 35 
  
Body Weight (g) 
 
Control 
 
 39.8 ± 0.0  189.6 ± 3.8  303.0 ± 3.9 354.7 ± 2.7 479.4 ± 6.0 648.0 ± 14.8 
0.006%@d10-12 
 
      309.9 ± 10.5 363.5 ± 6.4 491.8 ± 6.7 659.3 ± 7.8 
0.006%@d16-18 
 
         360.7 ± 3.5 484.5 ± 3.8 657.0 ± 6.3 
0.012%@d16-18 
 
         333.7 ± 15.7 471.0 ± 9.8 631.5 ± 15.4 
 Flock Uniformity  
(Coefficient of Variation) 
 
Control 
 
5.4 ± 0.1  12.5 ± 0.9  13.9 ± 0.8   10.7b ± 0.4 10.3b ± 0.4 10.3b ± 0.3 
0.006%@d10-12 
 
    12.0 ± 0.6 11.2b ± 0.5 10.6b ± 0.6 10.1b ± 0.7 
0.006%@d16-18 
 
      9.3b ± 0.4 9.8b ± 0.5 10.8b ± 0.7 
0.012%@d16-18        14.2a ± 1.8 13.3a ± 1.2 13.2a ± 1.0 
a,bIndicates significant difference between treatments at p ≤ 0.05. 
 
35 
 
  
35 
 
 
 
Figure [3-1] Trial 1—Oocyst shedding patterns (oocyst per gram (OPG) of feces) of 
Line A replacement pullets vaccinated with a live oocyst vaccine administered different 
concentrations of amprolium at different time periods through 35 days of age reared on 
fresh pine shavings beginning at d5 and continuing on an every other day basis through 
d35. 
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oocyst shedding of the 0.012% amprolium concentration group was depressed when 
compared to the group receiving no amprolium.  In addition, the peaks for both low level 
amprolium administrations showed higher peaks when compared to the control group. 
The first set of peaks in Line B pullets was shown to have occurred beginning at 
day 10 and continuing through day 13 with additional peaks varying according to 
treatment group.  The greatest magnitude of first peak shedding was observed in the 
control group followed by the higher concentration group administered at day 16.  The 
0.006% administration of amprolium beginning at day 10 yielded the lowest first peak 
level (Figure 3-2).  The group receiving 0.006% on days 10 through 12 had the highest 
second peak which occurred at day 19.  Following this peak, the shedding for this group 
decreased and eventually discontinued without further notable peaks.  In both groups 
receiving amprolium from day 16 to 18 second peaks were seen at similar magnitudes 
between days 17 and 19 followed by a decrease in shedding, and a relatively late peak 
again around day 26, again with similar magnitudes which greatly exceeded those of the 
control group.    
The Line C control group exhibited an initial peak in shedding at day eleven with 
a subsequent peak at day 17 of a greater magnitude than the first (Figure 3-3).  The 
group receiving amprolium beginning at day 10 showed peaks at the same intervals as 
the control group; however the magnitudes of both peaks were reduced relative to the 
control birds.  The first peak in shedding for the group receiving the highest level of 
amprolium was approximately three times greater than that of the other three groups 
with a subsequent peak at day 17 of a magnitude similar to that of the control group.  
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Late peaking was observed in groups receiving 0.006% amprolium on days 16 through 
18 with a peak of notable magnitude occurring around day 27 when shedding by all 
other treatment groups was negligible.   
Trial 2 
 No significant differences were observed, with regard to body weight data, 
between any treatment groups in any of the genetic lines of replacement pullets for the 
second trial of this experiment (Tables 3-6, 3-7, and 3-8).  In addition, no significant 
differences were shown among any of the three genetic lines when comparing 
uniformity among treatments for the duration of the trial. 
 The oocyst shedding observed in Line A pullets for trial two yielded a far greater 
magnitude than that which was observed in the first trial, particularly in the group 
receiving amprolium on days 10 through 12 (Figure 3-4) .  One peak in shedding was 
observed in control birds around day 15 post-vaccination.  In the early administration 
group, that first peak was suppressed—occurring on day 19, and showed more than a 
three-fold increase in magnitude compared to the control.  The second, higher peak 
occurred around day 27.  Peaking in the low level, late administration group was 
relatively non-existent when compared to all other groups.  High level, late 
administration yielded a very low magnitude peak at day 19 followed by an increased 
level four days following. 
The shedding patterns for Line B pullets in trial two differed slightly from that 
observed in trial one (Figure 3-5).  Initial peaks in shedding were seen at day 13, 
primarily in the high level administration group.  For the control group, the first peak 
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was observed at day 17, followed by a second peak of lesser magnitude at day 21, and 
again four days later.  The low level, early administration resulted in a minor peak at day 
13 followed by a second peak, approximately three folds higher, at day 17.  This peak 
was about half the level of the control peak that occurred on the same day.  After day 17, 
shedding decreased and no further peaks were observed.  The low level, late 
administration yielded the highest level of shedding at day 17 followed by a second, 
lesser peak at day 23.  High level administration exhibited the lowest, overall, amount of 
shedding in Line B.  Low magnitude peaks were observed at days 13, 17, and 23 post 
vaccination. 
Oocyst shedding in Line C for trial two varied slightly from what was observed 
in trial one (Figure 3-6).  The birds which did not receive amprolium showed the lowest 
overall shedding of all treatment groups.  Minor peaks were observed at days 11 and 19.  
Low level, early administration resulted in peak shedding at days 15 and 19, with the day 
19 peak having the highest magnitude of all treatment groups.  The low level, late 
administration group had one peak at day 17.  Birds receiving the high concentration of 
amprolium exhibited two peaks—the first was observed at day 13 with the second, 
which was approximately two-fold higher, not occurring until 23 days post vaccination.  
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Figure [3-2] Trial 1—Oocyst shedding patterns (OPG) of Line B replacement pullets 
vaccinated with a live oocyst vaccine administered different concentrations of 
amprolium at different time periods through 35 days of age reared on fresh pine shavings 
beginning at d5 and continuing on an every other day basis through d35. 
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Figure [3-3] Trial 1—Oocyst shedding patterns (OPG) of Line C replacement pullets 
vaccinated with a live oocyst vaccine administered different concentrations of 
amprolium at different time periods through 35 days of age reared on fresh pine shavings 
beginning at d5 and continuing on an every other day basis through d35. 
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Table [3-6] Trial 2—Body weights and flock uniformity of Line A replacement pullets vaccinated with a live oocyst vaccine 
administered different concentrations of amprolium at different time periods through 35 days of age reared on used litter. 
 
 Age (d) 
Treatment 0 10 16 21 28 35 
  
Body Weight (g) 
 
Control 
 
39.4 ± 0.0 135.2 ± 4.4 224.8 ± 8.7 297.7 ± 5.7 406.4 ± 7.7 540.1 ± 12.4 
0.006%@d10-12 
 
39.4 ± 0.0 144.4 ± 2.2 232.7 ± 5.0 294.0 ± 3.8 405.0 ± 7.0 551.6 ± 9.9 
0.006%@d16-18 
 
39.4 ± 0.0 137.4 ± 2.8 229.4 ± 6.7 307.1 ± 4.7 407.8 ± 11.7 537.5 ± 16.1 
0.012%@d16-18 
 
39.4 ± 0.0 134.5 ± 3.3 225.7 ± 6.1 296.6 ± 8.3 404.0 ± 6.3 542.1 ± 13.4 
 Flock Uniformity  
(Coefficient of Variation) 
 
Control 
 
 6.0 ± 0.2 19.6 ± 0.9 19.4 ± 1.5  17.3 ± 0.7 17.0 ± 1.1 17.2 ± 1.1 
0.006%@d10-12 
 
 6.0 ± 0.2 19.6 ± 0.3 17.9 ± 0.6 17.3 ± 0.6 16.1 ± 0.5 15.9 ± 0.7 
0.006%@d16-18 
 
 6.0 ± 0.2 20.2 ± 1.3 18.3 ± 1.5 16.2 ± 0.8 15.4 ± 0.8 15.8 ± 0.8 
0.012%@d16-18  6.1 ± 0.1 20.7 ± 0.8 20.4 ± 0.4 17.4 ± 0.9 15.9 ± 0.5 15.3 ± 0.4 
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Table [3-7] Trial 2—Body weights and flock uniformity of Line B replacement pullets vaccinated with a live oocyst vaccine 
administered different concentrations of amprolium at different time periods through 35 days of age reared on used litter. 
 
 Age (d) 
Treatment 0 10 16 21 28 35 
  
Body Weight (g) 
 
Control 
 
45.8 ± 0.0 194.6 ± 2.4 325.6 ± 4.8 399.1 ± 5.6 513.3 ± 5.7 662.3 ± 12.1 
0.006%@d10-12 
 
45.8 ± 0.0 188.4 ± 4.0 317.1 ± 13.4 385.0 ± 15.0 496.7 ± 13.2 652.7 ± 12.8 
0.006%@d16-18 
 
45.8 ± 0.0 191.1 ± 2.2 331.3 ± 1.2 404.7 ± 4.5 513.4 ± 5.1 669.6 ± 8.5 
0.012%@d16-18 
 
45.8 ± 0.0 189.5 ± 2.4 317.3 ± 9.1 388.5 ± 8.0 505.1 ± 7.3 561.1 ± 83.4 
 Flock Uniformity  
(Coefficient of Variation) 
 
Control 
 
6.2 ± 0.2 10.6 ± 0.7 11.7 ± 1.0  10.8 ± 0.4 10.9 ± 0.3 11.1 ± 0.6 
0.006%@d10-12 
 
6.4 ± 0.2 11.3 ± 0.9 9.5 ± 1.1 10.0 ± 0.8 9.6 ± 0.4 9.0 ± 0.4 
0.006%@d16-18 
 
6.2 ± 0.2 11.7 ± 0.9 9.3 ± 0.5 9.6 ± 0.4 10.0 ± 0.4 10.2 ± 0.4 
0.012%@d16-18 6.0 ± 0.2 12.3 ± 0.9 10.7 ± 1.1 10.0 ± 0.7 10.01 ± 0.5 10.0 ± 0.6 
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Table [3-8] Trial 2—Body weights and flock uniformity of Line C replacement pullets vaccinated with a live oocyst vaccine 
administered different concentrations of amprolium at different time periods through 35 days of age reared on used litter. 
 
 Age (d) 
Treatment 0 10 16 21 28 35 
  
Body Weight (g) 
 
Control 
 
35.3 ± 0.0 143.5 ± 2.9 251.3 ± 3.2 344.9 ± 6.0 466.1 ± 5.7 613.3 ± 7.3 
0.006%@d10-12 
 
35.3 ± 0.0 137.1 ± 3.7 252.2 ± 4.4 358.6 ± 7.5 478.3 ± 6.4 622.7 ± 10.8 
0.006%@d16-18 
 
35.3 ± 0.0 141.7 ± 3.0 249.4 ± 5.8 347.0 ± 5.5 465.3 ± 6.5 610.8 ± 14.9 
0.012%@d16-18 
 
35.3 ± 0.0 145.1 ± 3.0 254.2 ± 8.7  354.2 ± 5.4 473.6 ± 4.5 615.8 ± 21.5 
 Flock Uniformity  
(Coefficient of Variation) 
 
Control 
 
5.9 ± 0.2 14.1 ± 1.0 13.7 ± 1.3  11.8 ± 0.7 12.1 ± 0.5 12.7 ± 0.5 
0.006%@d10-12 
 
6.0 ± 0.2 14.9 ± 1.2 15.1 ± 1.3 12.3 ± 0.7 12.5 ± 0.6 12.7 ± 0.8 
0.006%@d16-18 
 
6.0 ± 0.2 16.6 ± 1.6 17.7 ± 1.8 14.3 ± 1.4 14.0 ± 1.2 14.0 ± 1.4 
0.012%@d16-18 6.0 ± 0.2 13.7 ± 1.5  14.1 ± 0.8 11.4 ± 1.1 11.6 ± 0.9 11.9 ± 0.9 
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Figure [3-4] Trial 2—Oocyst shedding patterns (OPG) of Line A replacement pullets 
vaccinated with a live oocyst vaccine administered different concentrations of 
amprolium at different time periods through 35 days of age reared on used litter 
beginning at d5 and continuing on an every other day basis through d35. 
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Figure [3-5] Trial 2—Oocyst shedding patterns (OPG) of Line B replacement pullets 
vaccinated with a live oocyst vaccine administered different concentrations of 
amprolium at different time periods through 35 days of age reared on used litter 
beginning at d5 and continuing on an every other day basis through d35. 
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Figure [3-6] Oocyst shedding patterns (OPG) of Line C replacement pullets vaccinated 
with a live oocyst vaccine administered different concentrations of amprolium at 
different time periods through 35 days of age reared on used litter beginning at d5 and 
continuing on an every other day basis through d35. 
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Discussion 
There exists a limited amount of research addressing the topic of amprolium 
administration in coccidiosis vaccinated pullets.  Because coccidiosis vaccination is the 
primary method for control of this disease and amprolium is often administered in the 
field in conjunction with vaccination, it is felt that further investigation of the effects of 
the medication should be performed.  One of the primary industry-based concerns 
addressed in this project was the expected decrease in performance of these replacement 
breeders during the early growth phases of the bird’s life following coccidiosis 
vaccination.  Previous research regarding amprolium administration has indicated that 
feeding programs can have a significant impact on the effects of amprolium particularly 
with regard to BWG.  Often, due to the fact that replacement pullet flocks are subjected 
to restricted feeding and skip-a-day feeding programs which are put into place 
specifically to hinder BWG; it is difficult to ascertain the effects of coccidial infection in 
these birds.  Ruff and Chute (1980) confirmed this after they compared a restricted 
feeding model and an ad libitum feeding model in conjunction with amprolium 
treatment.  Results from their experiment showed that weight gain was a valid parameter 
of analysis only in ad libitum fed birds, as the restricted feeding program contributed to 
the depressed weight gain of pullets.  This correlates with the data represented by this 
experiment in that no significant weight depression was observed at any time throughout 
the trial, although oocysts were actively being shed as was shown by the oocyst shedding 
pattern data. 
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In addition to issues regarding body weight and growth performance, personal 
communication with industry representatives has led to reports of inconsistent 
uniformity in vaccinated broiler breeder pullet flocks.  Results of the current experiment 
indicate that the effects of amprolium on flock uniformity are highly variable according 
to genetic line and litter conditions.  For example, in Line A, no indication was made to 
favor amprolium administration when birds were reared on new litter, whereas, when 
birds were reared on used litter in the second trial, trends indicated favorable outcomes 
when the later amprolium administrations were implemented.  In addition, Line B pullets 
revealed trends indicating an increased level of uniformity associated with amprolium 
administration when birds were reared on used litter.  However, in Line C pullets reared 
on new litter, there was an actual negative impact associated with amprolium, 
particularly with regard to the highest concentration when compared to all other 
treatment groups.  Further, when reared on used litter, trends indicate the greatest level 
of uniformity to reside in the groups receiving no amprolium in Line C pullets. 
Previous research has shown various indicators can be used in the evaluation of 
drug efficacy in poultry trials.  One of the considerations that is made in relation to the 
degree of efficacy of anticoccidial drugs, and thereby the degree of infection, is the 
counts of oocysts excreted by treated animals when compared to control groups (Gard & 
Tonkinson, 1970).  This trial implemented the use of oocyst counts to determine the 
effects of amprolium on post-vaccinal oocyst shedding with results indicating that the 
amprolium administered at different concentrations and time periods had varying effects 
on oocyst shedding between lines—taking into consideration both genetic line and litter 
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environment.  For example, when comparing Line A with both Line B and Line C, it is 
obvious that Line A pullets began shedding oocysts until slightly later than the other 
lines.  This could have significant influence on the effects of amprolium when taking 
into consideration the time of administration for the medication.  Another difference 
between lines is the suggested litter effect that exists in Lines B and C.  While in the first 
trial, both lines began shedding around day nine, it was apparent in the second trial, 
where used litter was present, that there was a delay in the onset of shedding.  This delay 
was not observed in Line A.  Taken together, these observations suggest that the effects 
of amprolium on coccidiosis vaccinated replacement broiler breeders with regard to 
growth performance and oocyst shedding are dependent on both the genetic makeup of 
the bird, as well as the environmental conditions in which they are reared—particularly 
in relation to oocyst shedding patterns.  It is therefore important that the type of bird be 
taken into account prior to the administration of amprolium in replacement breeding 
stock. 
  
   
50 
50 
CHAPTER IV 
EFFECT OF AMPROLIUM ADMINISTRATION ON BODY WEIGHT GAIN AND 
IMMUNITY DEVELOPMENT BASED ON INTESTINAL LESION DEVELOPMENT 
AND TOTAL OOCYST OUTPUT IN COCCIDIOSIS VACCINATED 
REPLACEMENT BROILER BREEDERS 
Introduction 
 Coccidiosis is an enteric disease caused by the protozoan parasite of the genus 
Eimeria.  This is one of the most significant diseases currently afflicting commercial 
poultry producers.  To date, there are nine species of Eimeria known to parasitize the 
intestine of the chicken, resulting in various complications such as intestinal lesion 
development, blood loss, mucoidal and hemorrhagic diarrhea, and in severe cases, death 
(McDougald and Fitz-Coy, 2008).  
 Various control measures exist in today’s industry with regard to control and 
prevention of this disease.  These consist, primarily, of an array of vaccination options as 
well as a variety of both synthetic and ionophorous chemical anticoccidial.  The more 
heavily relied upon method of control over the past few decades within the replacement 
broiler breeder industry is live oocyst vaccination (Williams et al., 2000).  This is due to 
the long term protective immunity to subsequent Eimeria infections that is provided by 
the immunological stimulation resulting from vaccination (Williams, 1994).  Both 
attenuated and non-attenuated vaccines have been successful in stimulating immunity to 
coccidial infection (Shirley and Millard, 1986; Long et al., 1986; Bedrnik et al., 1989; 
Shirley, 1989). 
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 In order for complete development of immunity to be achieved, it is necessary 
for complete and successful cycling of the parasite within the host to occur.  If parasites 
are, in any way, incapacitated prior to this happening, the immunity development can be 
deficient or in some cases completely negated.  The complete cycling begins with the 
initial peak in shedding which occurs approximately one week following vaccination 
wherein viable oocysts are excreted onto litter for sporulation and re-ingestion by the 
host (Chapman, 2000).  Although the concentration of oocysts administered for the 
purpose of vaccination is minimal, it is still possible to cause infection, and there are 
often negative effects associated with its employment including depressed flock 
uniformity and growth performance.  For this reason, it is common to see the 
concomitant administration of anticoccidials in vaccination protocols. 
 Various programs have been implemented within the replacement breeder 
industry including anticoccidial administration which allows for the shedding of enough 
oocysts to impart immunity while still preventing detrimental outbreaks, using drugs that 
have lost effectiveness, using drugs intermittently, or only in therapeutic instances (Reid 
et al., 1968; Long, 1979).  The use of anticoccidial programs which still allow for the 
development of immunity is vital in classes of birds such as these in which floor-rearing 
allows for access to feces, and where anticoccidial drugs will be removed prior to birds 
entering the laying period (Chapman, 1999).  Amprolium is one drug that has been 
suggested as a suitable option in the rearing of replacement breeders because it fits these 
criteria and has proven to be effective when high build up of infection is available in 
pens (Chapman, 1999). 
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 Various research has shown that amprolium can be successfully administered in 
effort to alleviate post-vaccinal reactions to coccidiosis vaccine without interfering 
appreciably with immunity development (Hu et al., 2000; Ruff and Chute, 1991; Ruff 
and Chute, 1980).  Although this information sheds a positive light on amprolium use, 
there still remains a certain degree of dispute over the proper timing of liquid amprolium 
administration for the use of controlling possible pathogenic effects of non-attenuated 
vaccines.  While certain sources state that amprolium should be used beginning ten days 
post-vaccination (Chapman, 1999; 2000; Chapman and Cherry, 1997) others believe that 
amprolium administration should commence 16-17 days following vaccination for the 
reduction of reaction to infective oocysts while not disrupting the cycling of the parasite, 
and thusly the development of immunity (Chapman et al., 2002). 
 The objective of this research trial was to determine and compare the effects of 
amprolium administration at different times and concentrations in vaccinated 
replacement broiler breeders on the development of immunity as measured by gross and 
microscopic lesion development and total oocyst output following clinical Eimeria 
challenge. 
Materials and Methods 
Experimental Design 
 This experiment was conducted in an environmentally controlled dark-out battery 
cage growing facility at the Texas A&M University Poultry Science Teaching, Research, 
and Extension Center in College Station, TX.  Animal care and husbandry were provided 
in accordance with an approved Texas A&M Institutional Animal Care and Use 
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(IACUC) protocol.  Both trials of this experiment implemented an experimental design 
consisting of four treatment groups present in each of three genetic lines of birds.  Five 
replicate pens were placed for each treatment group for a final total of 60 pens.  The 
three genetic lines were denoted as Lines A, B, and C.  Of the four treatment groups, one 
group was administered amprolium from days 10 through 12 at a concentration of 
0.006%, another was administered from day 16 through 18 at the same concentration, 
while the other was administered from day 16 through 18 at a concentration of 0.012%.  
A negative control was maintained for each genetic line in which access to the main line 
water source was maintained for the duration of the trial.  Following a 35 day grow-out 
period, eight pullets were removed from each of the floor pens, weighed, and randomly 
placed according to their strain and experimental treatment into 48 battery cages 
containing ten birds each for a total of 480 birds.  Following a brief acclimation period 
of three to six days, a mixed species field strain inoculum was administered to all birds 
via oral gavage.  Experimental parameters evaluated included body weight gain (BWG), 
total oocyst output associated with experimental challenge (oocysts shed per gram 
(OPG) of feces), gross lesion development, and microscopic lesion development.   
Body Weight Gain 
 Initial body weights were taken prior to challenge administration as well as seven 
days post challenge in order to determine BWG for the challenge period. 
Total Oocyst Output Determination 
 For ten days following the initial challenge, fecal contents for each pen were 
collected and weighed daily to determine total fecal output for the 24 hour period.  Fecal 
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matter for each pen was homogenized and, from this, a sample obtained in a labeled bag 
to be used for oocyst per gram calculations.  Each sample was weighed, diluted at a 3:1 
ratio of water to feces, and 10 µL of fecal suspension were extracted and loaded into a 
hemacytometer using a 200µL pipette to be observed microscopically for oocyst 
presence.  A standard light microscope and a 20× objective were used to determine the 
number of non-sporulated oocysts present in each milliliter of sample.  This number was 
then used to calculate the total number of oocysts excreted by the corresponding pen of 
birds and adjusted on to a per bird, per day basis. 
Experimental Animals and Rearing  
Pullets of each line were randomly selected by genetic line at 35 days of age 
according to average body weights, and placed into battery brooders in an 
environmentally controlled, dark-out rearing facility.  Birds were placed into cages 
randomly according to strain and treatment groups to achieve a final count of ten birds 
per cage.  Breed specific grower rations were provided in a 3/4 skip-a-day feeding 
regime (Table 4-1) and fresh water was available ad libitum for the duration of the trial.  
An industry standard lighting schedule of eight hours per day of light was followed for 
the duration of the trial. 
Pullets were allowed to acclimate to the new environment for three days in trial 
one and six days in trial two, after which time they received an oral challenge inoculum 
containing multiple species of Eimeria.   
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[Table 4-1]  Feed allocation on a per bird, per day basis for each genetic line fed 
throughout the challenge period. 
 
 Trial 1 Trial 2 
Line A 38g 41g 
Line B 45g 47g 
Line C 43g 45g 
   
 
Vaccination and Amprolium Administration  
The commercially available coccidiosis vaccine (Coccivac®-D; 
Intervet/Schering-Plough Animal Health; Summit, NJ), a non-attenuated live oocyst 
coccidiosis vaccine for replacement broiler breeders was administered at the 
manufacturer recommended dose of 0.25 mL/bird on day of hatch via commercial spray 
cabinet in the commercial hatchery providing each genetic line of replacement breeders. 
 In both trials, each genetic line of pullets received amprolium (Amprol® 9.6% 
Oral Solution; Huvepharma; Sofia, Bulgaria) according to one of four administration 
protocols.  One group of each genetic line was a negative control and provided an 
unmedicated water supply for the duration of the trial while the three amprolium 
administrations consisted of a 0.006% concentration on days 10 through 12, a 0.006% 
concentration on days 16 through 18, and a 0.012% concentration on days 16 through 
18.    
Eimeria Challenge 
Species included in the challenge inoculum for trial one included E. acervulina 
(80,000 oocysts/bird), E. maxima (20,000 oocysts/bird), E. tenella (20,000 oocysts/bird), 
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and E. necatrix (15,000 oocysts/bird) for a total of 135,000 oocysts administered to each 
bird.  Species included in the challenge inoculum for trial two included E. acervulina 
(139,500 oocysts/bird), E. mivati (98,000 oocysts/bird), E. necatrix (28,000 
oocysts/bird), E. maxima (42,000 oocysts/bird), E. tenella (35,000 oocysts/bird), and E. 
brunetti (42,000 oocysts/bird) for a total of 384,500 oocysts being administered to each 
bird.  In both trials challenge was administered to each bird via oral crop gavage. 
Indices of Eimeria Challenge  
 Seven days post-challenge, body weights were collected from all challenged 
subjects, half of each pen (N=240) was euthanized, and the duodenum, jejunum, ileum, 
and ceca removed for gross and microscopic lesion assessment.  Gross lesion 
development and severity were assessed on a scale of 0 to 4 using the methods described 
by Johnson and Reid (1970).   
Microscopic lesion development and oocyst presence were evaluated by 
removing intestinal contents and taking a scraping of each individual section of 
gastrointestinal tract—duodenum, ileum, and cecum.  Each scraping was placed on a 
microscope slide, covered, and observed under 200× magnification to determine the 
severity of infection on a scale of 0 to 4 according to the level of oocyst presence. 
Statistical Analysis 
The experimental parameters from this trial were subject to a one way ANOVA 
(SPSS v. 11).  Means were separated using Duncan’s Multiple Range test and deemed 
statistically different at p ≤ 0.05 (SYSTAT, 2001). 
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Results  
Trial 1 
When comparing pre- and post-challenge body weights, as well as BWG that 
occurred following challenge, no significant differences were observed between 
treatment groups for Line A pullets.  In addition, gross and microscopic lesion 
development between groups did not exhibit significant differences in any of the regions 
examined.  However, total oocyst excretion in Line A pullets administered the 0.006% 
amprolium on days 10 through 12 was significantly lower than either of the other groups 
receiving amprolium, but was not different than that of the control group (Table 4-2).  
Additionally, the 0.006% amprolium administered on days 16 through 18 yielded total 
oocyst output significantly higher than that of the control group.   
While no differences were observed in pre- or post-challenge body weights 
between treatment groups, Line B pullets receiving 0.006% amprolium administration at 
days 16 through 18 did exhibit significantly (p ≤ 0.05) higher BWG when compared 
with the group receiving no amprolium (Table 4-3).  Additionally, significantly (p ≤ 
0.05) higher gross lesion development was observed in the mid-gut of the birds receiving 
the 0.012% amprolium concentration at days 16 through 18 when compared to that of 
the other groups receiving amprolium (Table 4-3).  However, no differences were seen 
in either the gross duodenal or cecal lesion development.  Additionally, no differences 
were observed with regard to microscopic lesion development in any of the three regions 
of the intestine or in the total oocyst output data.   
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Table [4-2] Trial 1—Post-challenge BWG, gross and microscopic lesion development, 
and total oocyst output (per bird) over a seven day period of vaccinated Line A 
replacement pullets administered a clinical Eimeria challenge.  
 
Post-Challenge BWG (g) 
Treatment Pre-Challenge BW Post-Challenge BW Weight Gained 
Control 586.2 ± 18.65 627.8 ± 19.77 41.7 ± 7.23 
0.006%@d10-12 578.7 ± 9.46 623.5 ± 11.20 44.8 ± 12.90 
0.006%@d16-18 604.4 ± 10.03 634.5 ± 14.38 30.1 ± 14.40 
0.012%@d16-18 586.2 ± 20.38 628.7 ± 17.28 42.5 ± 8.83 
Gross Lesion Development 
 Duodenum Ileum Ceca 
Control 0 ± 0.00 0.45 ± 0.15 0.85 ± 0.24 
0.006%@d10-12 0 ± 0.00 0.55 ± 0.27 0.95 ± 0.21 
0.006%@d16-18 0 ± 0.00 0.45 ± 0.15 0.75 ± 0.21 
0.012%@d16-18 0 ± 0.00 0.25 ± 0.13 0.85 ± 0.10 
Microscopic Lesion Development 
 Duodenum Ileum Ceca 
Control 0.11 ± 0.11 0.56 ± 0.18 0.89 ± 0.20 
0.006%@d10-12 0 ± 0.00 0.50 ± 0.17 0.70 ± 0.21 
0.006%@d16-18 0.20 ± 0.13 0.90 ± 0.18 0.90 ± 0.23 
0.012%@d16-18 0.10 ± 0.10 0.90 ± 0.18 1.00 ± 0.21 
Total Oocyst Output 
 Oocysts Excreted (per bird) 
Control 6,092,586bc ± 1,128,225 
0.006%@d10-12 4,539,235c ± 180,748 
0.006%@d16-18 10,250,949a ± 1,273,102 
0.012%@d16-18 8,609,484ab ± 1,041,040 
a-cIndicates significant differences at p ≤ 0.05. 
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Table [4-3] Trial 1—Post-challenge BWG, gross and microscopic lesion development, 
and total oocyst output (per bird) over a seven day period of vaccinated Line B 
replacement pullets administered a clinical Eimeria challenge.  
 
Post-Challenge BWG (g) 
Treatment Pre-Challenge BW Post-Challenge BW Weight Gained 
Control 715.3 ± 13.67 760.8 ± 12.67 45.6b ± 5.09 
0.006%@d10-12 711.2 ± 15.35 764.4 ± 17.32 53.2ab ± 5.81 
0.006%@d16-18 695.1 ± 15.54 759.9 ± 15.26 64.8a ± 7.27 
0.012%@d16-18 709.5 ± 11.13 760.6 ± 12.60 51.1ab ± 9.21 
Gross Lesion Development 
 Duodenum Ileum Ceca 
Control 0 ± 0.00 0.32ab ± 0.15 0.95 ± 0.22 
0.006%@d10-12 0 ± 0.00 0.20b ± 0.13 0.60 ± 0.15 
0.006%@d16-18 0 ± 0.00 0.11b ± 0.10 0.74 ± 0.21 
0.012%@d16-18 0 ± 0.00 0.55a ± 0.13 0.65 ± 0.21 
Microscopic Lesion Development 
 Duodenum Ileum Ceca 
Control 0.11 ± 0.11 0.67 ± 0.17 0.67 ± 0.17 
0.006%@d10-12 0 ± 0.00 0.80 ± 0.20 0.70 ± 0.15 
0.006%@d16-18 0 ± 0.00 0.30 ± 0.15 0.60 ± 0.22 
0.012%@d16-18 0 ± 0.00 0.70 ± 0.21 0.90 ± 0.23 
Total Oocyst Output 
 Oocysts Excreted (per bird) 
Control 10,613,380 ± 2,539,737 
0.006%@d10-12 10,678,137 ± 2,727,683 
0.006%@d16-18 8,308,315 ± 1,634,414 
0.012%@d16-18 5,298,748 ± 999,439 
a-bIndicates significant differences at p ≤ 0.05. 
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Table [4-4] Trial 1—Post-challenge BWG, gross and microscopic lesion development, 
and total oocyst output (per bird) over a seven day period of vaccinated Line C 
replacement pullets administered a clinical Eimeria challenge.  
 
Post-Challenge BWG (g) 
Treatment Pre-Challenge BW Post-Challenge BW Weight Gained  
Control 651.0 ± 16.31 710.4 ± 16.02 59.4 ± 14.23 
0.006%@d10-12 656.5 ± 13.33 711.3 ± 11.35 54.8 ± 12.54 
0.006%@d16-18 649.1 ± 7.30 708.2 ± 9.82 59.1 ± 9.00 
0.012%@d16-18 640.1 ± 6.96 693.4 ± 6.85 53.3 ± 6.30 
Gross Lesion Development 
 Duodenum Ileum Ceca 
Control 0 ± 0.00 0.30 ± 0.15 0.85 ± 0.20 
0.006%@d10-12 0 ± 0.00 0.40 ± 0.15 0.75 ± 0.23 
0.006%@d16-18 0 ± 0.00 0.25 ± 0.10 1.05 ± 0.22 
0.012%@d16-18 0 ± 0.00 0.45 ± 0.10 0.90 ± 0.20 
Microscopic Lesion Development 
 Duodenum Ileum Ceca 
Control 0b ± 0.00 1.10 ± 0.10 0.70 ± 0.15 
0.006%@d10-12 0b ± 0.00 1.00 ± 0.15 0.50 ± 0.17 
0.006%@d16-18 0b ± 0.00 0.90 ± 0.18 1.00 ± 0.15 
0.012%@d16-18 0.40a ± 0.16 0.90 ± 0.23 0.90 ± 0.23 
Total Oocyst Output 
 Oocysts Excreted (per bird) 
Control 17,041,719 ± 1,908,207 
0.006%@d10-12 14,299,320 ± 1,360,287 
0.006%@d16-18 14,840,499 ± 3,510,965 
0.012%@d16-18 16,833,332 ± 2,076,113 
a-bIndicates significant differences at p ≤ 0.05. 
 
  
   
61 
61 
In the Line C pullets, no differences were observed when comparing pre- and 
post-challenge body weights or BWG.  Also, no significant differences were observed 
with regard to gross lesion development in any region examined.  And while 
significantly (p ≤ 0.05) higher microscopic lesion development was observed in the 
duodenal loop of those receiving the 0.012% amprolium administration at days 16 
through 18 when compared to all other treatment groups (Table 4-4), no differences 
were seen in either the ileum or the ceca.  No differences were observed in the total 
oocyst shedding between treatments. 
Trial 2 
 No significant differences were observed in Line A replacement pullets with 
regard to pre- or post-challenge body weights, nor were they observed between 
treatments when comparing BWG for the challenge period (Table 4-5).  Additionally, no 
differences were observed in total oocyst output for the duration of the challenge. 
In Line B pullets, no differences were shown in pre- or post-challenge body 
weights, or in BWG.  With regard to gross lesion development in the duodenum and 
ileum, no differences were observed; however, those pullets subjected to the 0.006% 
amprolium concentrations at days 10 through 12 and 16 through 18 exhibited a 
significantly higher degree of gross lesion development in the ceca when compared to 
the pullets which did not receive any amprolium (Table 4-6).  No differences were 
shown by the microscopic lesion data for all gut regions.  Total oocyst output data for 
the challenge in Line B, also did not show significant differences between treatments.   
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Table [4-5] Trial 2—Post-challenge BWG, gross and microscopic lesion development, 
and total oocyst output (per bird) over a seven day period of vaccinated Line A 
replacement pullets administered a clinical Eimeria challenge.  
 
Post-Challenge BWG (g) 
Treatment Pre-Challenge BW Post-Challenge BW Weight Gained  
Control 496.0 ± 20.53 607.7 ± 20.49 111.7 ± 4.34 
0.006%@d10-12 502.3 ± 13.16 620.7 ± 14.48 118.3 ± 5.35 
0.006%@d16-18 493.0 ± 12.66 602.3 ± 13.80 109.4 ± 4.69 
0.012%@d16-18 499.0 ± 13.41 604.3 ± 20.81 105.4 ± 11.64 
Gross Lesion Development 
Duodenum Ileum Ceca 
Control 0 ± 0.00 0.75 ± 0.22 0.65 ± 0.13 
0.006%@d10-12 0 ± 0.00 0.50 ± 0.15 0.45 ± 0.17 
0.006%@d16-18 0 ± 0.00 0.95 ± 0.22 0.60 ± 0.24 
0.012%@d16-18 0 ± 0.00 0.80 ± 0.16 0.50 ± 0.17 
Microscopic Lesion Development 
 Duodenum Ileum Ceca 
Control 0 ± 0.00 0.10 ± 0.10 1.10 ± 0.23 
0.006%@d10-12 0.11 ± 0.11 0.10 ± 0.10 1.50 ± 0.17 
0.006%@d16-18 0 ± 0.00 0 ± 0.00 0.89 ± 0.20 
0.012%@d16-18 0 ± 0.00 0.30 ± 0.15 1.10 ± 0.18 
Total Oocyst Output 
 Oocysts Excreted (per bird) 
Control 106,985 ± 65,426 
0.006%@d10-12 138,838 ± 90,874 
0.006%@d16-18 737,701± 277,378 
0.012%@d16-18 504,989± 296,448 
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Table [4-6] Trial 2—Post-challenge BWG, gross and microscopic lesion development, 
and total oocyst output (per bird) over a seven day period of vaccinated Line B 
replacement pullets administered a clinical Eimeria challenge.  
 
Post-Challenge BWG (g) 
Treatment Pre-Challenge BW Post-Challenge BW Weight Gained  
Control 621.4 ± 9.62 756.7 ± 14.32 135.3 ± 9.01 
0.006%@d10-12 619.0 ± 7.16 755.4 ± 12.99 136.4 ± 9.06 
0.006%@d16-18 627.0 ± 7.57 763.6 ± 11.91 136.6 ± 6.56 
0.012%@d16-18 631.2 ± 12.49 767.3 ± 12.86 137.3 ± 4.48 
Gross Lesion Development 
Duodenum Ileum Ceca 
Control 0 ± 0.00 0.80 ± 0.13 0.95a ± 0.28 
0.006%@d10-12 0 ± 0.00 0.79 ± 0.19 0.47b ± 0.21 
0.006%@d16-18 0 ± 0.00 0.70 ± 0.15 0.35b ± 0.17 
0.012%@d16-18 0 ± 0.00 0.65 ± 0.18 0.60ab ± 0.17 
Microscopic Lesion Development 
 Duodenum Ileum Ceca 
Control 0.10 ± 0.10 0.30 ± 0.15 0.70 ± 0.21 
0.006%@d10-12 0.36 ± 0.15 0.36 ± 0.20 0.91 ± 0.28 
0.006%@d16-18 0.30 ± 0.15 0.20 ± 0.13 1.30 ± 0.21 
0.012%@d16-18 0 ± 0.00 0 ± 0.00 0.56 ± 0.34 
Total Oocyst Output 
 Oocysts Excreted (per bird) 
Control 1,205,774 ± 421,133 
0.006%@d10-12 494,845 ± 367,413 
0.006%@d16-18 1,224,777 ± 1,126,239 
0.012%@d16-18 558,795 ± 243,232 
a-bIndicates significant differences at p ≤ 0.05. 
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Table [4-7] Trial 2—Post-challenge BWG, gross and microscopic lesion development, 
and total oocyst output (per bird) over a seven day period of vaccinated Line C 
replacement pullets administered a clinical Eimeria challenge.  
 
Post-Challenge BWG (g) 
Treatment Pre-Challenge BW Post-Challenge BW Weight Gained  
Control 574.9 ± 12.19 692.5a ± 15.61 117.6 ± 6.68 
0.006%@d10-12 580.0 ± 10.56 694.8a ± 11.75 114.6 ± 4.83 
0.006%@d16-18 573.9 ± 11.05 687.0ab ± 15.23 113.1 ± 5.84 
0.012%@d16-18 563.2 ± 9.98 669.1b ± 11.71 105.9 ± 5.91 
Gross Lesion Development 
Duodenum Ileum Ceca 
Control 0 ± 0.00 0.85 ± 0.15 0.50 ± 0.22 
0.006%@d10-12 0 ± 0.00 0.95 ± 0.13 0.35 ± 0.15 
0.006%@d16-18 0 ± 0.00 0.95 ± 0.15 0.75 ± 0.21 
0.012%@d16-18 0 ± 0.00 0.80 ± 0.10 0.50 ± 0.16 
Microscopic Lesion Development 
 Duodenum Ileum Ceca 
Control 0 ± 0.00 0 ± 0.00 0.70 ± 0.21 
0.006%@d10-12 0.20 ± 0.13 0.20 ± 0.13 0.60 ± 0.22 
0.006%@d16-18 0.10 ± 0.10 0.40 ± 0.16 0.60 ± 0.22 
0.012%@d16-18 0.30 ± 0.15 0.20 ± 0.13 0.90 ± 0.28 
Total Oocyst Output 
 Oocysts Excreted (per bird) 
Control 10,363,825 ± 8,507,180 
0.006%@d10-12 718,629 ± 680,587 
0.006%@d16-18 597,793 ± 288,788 
0.012%@d16-18 493,366 ± 265,856 
a-bIndicates significant differences at p ≤ 0.05. 
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While differences were not shown in pre-challenge body weights or BWG in 
Line C pullets, a higher final body weight following the challenge period was observed 
in both the control group and the group receiving the 0.006% amprolium at days 10 
through 12 than those receiving the highest concentration of amprolium (Table 4-7).  
When comparing both gross and microscopic lesion development between treatments for 
all areas of the intestine, no significant differences were observed.  No differences were 
shown between treatments with regard to total oocyst output. 
Discussion 
 Previous research has shown that BWG is often not a sufficient means of 
determining the significance of the effect of Eimeria infection on growth inhibition in 
birds which are restrict-fed due to the already present reduction in weight gain which 
results from the limited intake (Ruff and Chute, 1980).  This helps explain the lack of 
differences between treatment groups within genetic lines, with the exception of Line B 
pullets in the first trial.  Due to the suppression that already exists as a result of the 
restricted feeding program, it is difficult to attribute a lack of BWG directly to challenge 
in these trials. 
 Because weight gain is not deemed a sufficient determinant of challenge effects, 
lesion score assessment in challenged birds is considered to be a more sensitive measure 
of the level of infection in challenged birds (Karlsson and Reid, 1978; Ruff and Chute, 
1980; Ruff et al., 1991).  This clarifies the increased BWG observed in Line B pullets in 
trial one, as differences in lesion development did not exist between the groups 
exhibiting differences in BWG.   
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 Another indicator of the level of immunity development that exists in birds is the 
number of oocysts excreted following infection (Lillehoj and Ruff, 1987).  The 
differences that were observed in the Line A pullets in trial one indicate an improvement 
in immunity development when amprolium was administered beginning on day 10; 
however the decrease in oocyst output was not found in coordination with decreases in 
lesion development or post-challenge BWG.  
 Comprehensively, taking into account all parameters of measurement including 
post-challenge BWG as well as gross and microscopic lesion development and total 
oocyst output by all treatment groups, although trends were indicative, no direct 
indication of an inhibition of immunity development was shown to be associated with 
amprolium administration in replacement broiler breeders of the three genetic lines 
examined.  This is in accordance with previous research evaluating amprolium use in 
broiler breeders in which pullets previously exposed to coccidia, and administered 
amprolium while on a restricted feeding program were resistant to subsequent challenge 
infection which supports the premise that vaccination (previous exposure) in accordance 
with amprolium administration does not inhibit immunity development (Ruff and Chute, 
1980; Ruff et al., 1991).    
 
 
  
   
67 
67 
CHAPTER V 
CONCLUSION 
Currently in the poultry industry, nearly 100 percent of replacement breeding 
stock are vaccinated against coccidiosis using a live oocyst vaccine.  However, reports 
from the field have indicated negative effects on weight gain and uniformity relating to 
the inherent infection associated with vaccination.  In effort to combat these negative 
reactions, integrators have implemented an amprolium medication program to control 
the infection with further concerns of inhibited immunity development.  Various experts 
in the field disagree on the proper administration protocol to implement in order to 
minimize this inhibition.  The main objectives of this experiment were to determine and 
compare the effects of amprolium administration at specific times and concentrations on 
performance and immunity development in separate genetic lines of coccidiosis 
vaccinated replacement broiler breeders. 
The results of this research indicate that effects of amprolium at different 
concentrations administered at different time points on both flock uniformity and oocyst 
cycling vary according to genetic line and litter conditions.  While no apparent 
advantage was associated with amprolium administration with respect to body weight in 
any of the genetic lines, effects on uniformity were variable by line.  While one line may 
have reacted positively to the amprolium administration when raised on used litter, the 
amprolium could have had little to no effect when that same line was raised on fresh 
litter.  Additionally, one line was negatively affected by certain concentrations on new 
litter yet reacted positively to the medication when reared on used litter.  Litter condition 
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also appears to alter the pattern and magnitude of oocyst output in certain genetic lines.  
On fresh pine shavings, the first identifiable peak was observed on days 9 to 11 in 
certain lines while not appearing until days 17 to 20 in others, whereas on built up litter, 
the peak of oocyst output is delayed in lines exhibiting early peaking on fresh litter but 
occurs at similar times in the later peaking line.  The magnitude of oocyst output and 
number of identifiable peaks are influenced by genetic line. 
Parameters used to evaluate immunity generation included post-challenge BWG, 
lesion development following challenge, and total number of oocysts shed per bird.  Line 
B exhibited a significantly higher degree of weight gain in the group receiving the low 
concentration at days 16 through 18 as compared to the control, which indicates better 
immunity development, while all other groups were the same.  The same treatment in 
Line B appeared to decrease lesion development in both the mid-gut and ceca in 
challenged pullets, although there were no notable effects on total oocyst output.  In Line 
C, significantly higher microscopic lesion scores were associated with the highest 
concentration administration compared to all other groups.  Here again, results varied 
with genetic line.   
These data indicate that genetic line and litter environment can have significant 
impacts on flock uniformity as well as post-vaccination oocyst cycling in vaccinated 
replacement pullets that receive amprolium.  These criteria should be taken into account 
when considering the appropriate coccidiosis treatment of replacement breeding stock.
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